Non-invasive Imaging of Idiopathic Pulmonary Fibrosis Using Cathepsin Protease Probes

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Withana, Nimali P ^a   Ma, Xiaowei ^a   McGuire, Helen M ^a   Verdoes, Martijn ^a,e   Van Der Linden, Wouter A ^a   Ofori, Leslie O ^a   Zhang, Ruiping ^a   Li, Hao ^a   Sanman, Laura E ^a   Wei, Ke ^a   Yao, Shaobo ^b   Wu, Peilin ^b   Li, Fang ^b   Huang, Hui ^c   Xu, Zuojun ^c   Wolters, Paul J ^d   Rosen, Glenn D ^a   Collard, Harold R ^d   Zhu, Zhaohui ^b   Cheng, Zhen ^a   Bogyo, Matthew ^a   more..

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Nuclear Medicine ^*  (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CATHEPSIN; COPPER; GALLIUM; MOLECULAR PROBE;

ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MODEL; FLUORESCENCE IMAGING; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOLOGY; LUNG; MACROPHAGE ACTIVATION; METABOLISM; MOLECULAR PROBE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES;

ANIMALS; BLEOMYCIN; CATHEPSINS; COPPER RADIOISOTOPES; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GALLIUM RADIOISOTOPES; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MACROPHAGE ACTIVATION; MOLECULAR PROBES; OPTICAL IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84955451151     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19755     Document Type: Article

References (40)

1. Hardie, W. D., Glasser, S. W. & Hagood, J. S. Emerging concepts in the pathogenesis of lung fibrosis. The American journal of pathology 175, 3-16, doi: 10.2353/ajpath.2009.081170 (2009).
2. Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z. & Oster, G. Incidence and prevalence of idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 174, 810-816, doi: 10.1164/rccm.200602-163OC (2006).
3. Raghu, G. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. The Lancet. Respiratory medicine 2, 566-572, doi: 10.1016/S2213-2600(14)70101-8 (2014).
4. Coward, W. R., Saini, G. & Jenkins, G. The pathogenesis of idiopathic pulmonary fibrosis. Therapeutic advances in respiratory disease 4, 367-388, doi: 10.1177/1753465810379801 (2010).
5. Caminati, A. & Harari, S. IPF: New insight in diagnosis and prognosis. Respiratory medicine 104 Suppl 1, S2-10, doi: 10.1016/j. rmed.2010.03.012 (2010).
6. Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. The New England journal of medicine 370, 2071-2082, doi: 10.1056/NEJMoa1402584 (2014).
7. Fonovic, M. & Turk, B. Cysteine cathepsins and extracellular matrix degradation. Biochimica et biophysica acta 1840, 2560-2570, doi: 10.1016/j.bbagen.2014.03.017 (2014).
8. Gibbons, M. A. et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. American journal of respiratory and critical care medicine 184, 569-581, doi: 10.1164/rccm.201010-1719OC (2011).
9. Desai, B. et al. Differential expression of monocyte/macrophage-selective markers in human idiopathic pulmonary fibrosis. Experimental lung research 37, 227-238, doi: 10.3109/01902148.2010.538132 (2011).
10. Prasse, A. et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 179, 717-723, doi: 10.1164/rccm.200808-1201OC (2009).
11. Tiev, K. P. et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. The European respiratory journal 38, 1355-1360, doi: 10.1183/09031936.00004711 (2011).
12. Aono, Y. et al. Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. American journal of respiratory and critical care medicine 185, 525-536, doi: 10.1164/rccm.201103-0561OC (2012).
13. Chapman, H. A., Riese, R. J. & Shi, G. P. Emerging roles for cysteine proteases in human biology. Annual review of physiology 59, 63-88, doi: 10.1146/annurev.physiol.59.1.63 (1997).
14. Wolters, P. J. & Chapman, H. A. Importance of lysosomal cysteine proteases in lung disease. Respiratory research 1, 170-177, doi: 10.1186/rr29 (2000).
15. Takeyabu, K. et al. Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. The European respiratory journal 12, 1033-1039 (1998).
16. Koslowski, R., Knoch, K., Kuhlisch, E., Seidel, D. & Kasper, M. Cathepsins in bleomycin-induced lung injury in rat. The European respiratory journal 22, 427-435 (2003).
17. Conus, S. & Simon, H. U. Cathepsins and their involvement in immune responses. Swiss medical weekly 140, w13042, doi: 10.4414/smw.2010.13042 (2010).
18. Verdoes, M. et al. A nonpeptidic cathepsin S activity-based probe for noninvasive optical imaging of tumor-associated macrophages. Chemistry & biology 19, 619-628, doi: 10.1016/j.chembiol.2012.03.012 (2012).
19. Blum, G., von Degenfeld, G., Merchant, M. J., Blau, H. M. & Bogyo, M. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nature chemical biology 3, 668-677, doi: 10.1038/nchembio.2007.26 (2007).
20. Greenbaum, D., Medzihradszky, K. F., Burlingame, A. & Bogyo, M. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chemistry & biology 7, 569-581 (2000).
21. Segal, E. et al. Detection of intestinal cancer by local, topical application of a quenched fluorescence probe for cysteine cathepsins. Chemistry & biology 22, 148-158, doi: 10.1016/j.chembiol.2014.11.008 (2015).
22. Verdoes, M. et al. Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. Journal of the American Chemical Society 135, 14726-14730, doi: 10.1021/ja4056068 (2013).
23. Cox, T. R. & Erler, J. T. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Disease models & mechanisms 4, 165-178, doi: 10.1242/dmm.004077 (2011).
24. Kato, D. et al. Activity-based probes that target diverse cysteine protease families. Nature chemical biology 1, 33-38, doi: 10.1038/nchembio707 (2005).
25. Chang, S. H. et al. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer research 69, 4537-4544, doi: 10.1158/0008-5472.CAN-08-4539 (2009).
26. Lyo, V. et al. Active cathepsins B, L, and S in murine and human pancreatitis. American journal of physiology. Gastrointestinal and liver physiology 303, G894-903, doi: 10.1152/ajpgi.00073.2012 (2012).
27. Withana, N. P. et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer research 72, 1199-1209, doi: 10.1158/0008-5472.CAN-11-2759 (2012).
28. Walters, D. M. & Kleeberger, S. R. Mouse models of bleomycin-induced pulmonary fibrosis. Current protocols in pharmacology/editorial board, S.J. Enna Chapter 5, Unit 5 46, doi: 10.1002/0471141755.ph0546s40 (2008).
29. Richards, T. J. et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine 185, 67-76, doi: 10.1164/rccm.201101-0058OC (2012).
30. Moore, B. B. & Hogaboam, C. M. Murine models of pulmonary fibrosis. American journal of physiology. Lung cellular and molecular physiology 294, L152-160, doi: 10.1152/ajplung.00313.2007 (2008).
31. Wilson, M. S. et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. The Journal of experimental medicine 207, 535-552, doi: 10.1084/jem.20092121 (2010).
32. Bergeron, A. et al. Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role for TGF-beta and IL-10. The European respiratory journal 22, 69-76 (2003).
33. Pan, L. H., Ohtani, H., Yamauchi, K. & Nagura, H. Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathology international 46, 91-99 (1996).
34. Izbicki, G., Segel, M. J., Christensen, T. G., Conner, M. W. & Breuer, R. Time course of bleomycin-induced lung fibrosis. International journal of experimental pathology 83, 111-119 (2002).
35. Cutter, J. L. et al. Topical application of activity-based probes for visualization of brain tumor tissue. PloS one 7, e33060, doi: 10.1371/journal.pone.0033060 (2012).
36. Kasabova, M. et al. Regulation of TGF-beta1-Driven Differentiation of Human Lung Fibroblasts: Emerging Roles of Cathepsin B and Cystatin C. The Journal of biological chemistry, doi: 10.1074/jbc.M113.542407 (2014).
37. Martin, S. L. et al. Association of airway cathepsin B and S with inflammation in cystic fibrosis. Pediatric pulmonology 45, 860-868, doi: 10.1002/ppul.21274 (2010).
38. Caravan, P. et al. Molecular magnetic resonance imaging of pulmonary fibrosis in mice. American journal of respiratory cell and molecular biology 49, 1120-1126, doi: 10.1165/rcmb.2013-0039OC (2013).
39. Krishna, G. et al. PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. The American journal of pathology 158, 997-1004, doi: 10.1016/S0002-9440(10)64046-1 (2001).
40. Young, L. R., Borchers, M. T., Allen, H. L., Gibbons, R. S. & McCormack, F. X. Lung-restricted macrophage activation in the pearl mouse model of Hermansky-Pudlak syndrome. Journal of immunology 176, 4361-4368 (2006).